Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
AbbVie's first-quarter results top expectations as arthritis drugs fuel growth
07:36am, Friday, 26'th Apr 2024
AbbVie Inc. on Friday reported first-quarter results that beat expectations, even as sales of blockbuster autoimmune drug Humira continued to fall amid new, lower-cost competition.
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
08:48am, Thursday, 25'th Apr 2024
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to
March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys
08:10am, Thursday, 25'th Apr 2024
March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
01:06pm, Wednesday, 24'th Apr 2024
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline
4 Large Drug Stocks to Hold on to Amid Industry Challenges
11:11am, Wednesday, 24'th Apr 2024
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining i
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
10:21am, Wednesday, 24'th Apr 2024
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes
04:41pm, Tuesday, 23'rd Apr 2024
Because dividend investing has such an impressive track record of beating non-dividend-paying stocks, many investors buy Dividend Aristocrats for their portfolios. It's not a bad strategy to begin wit
Gear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics
10:21am, Tuesday, 23'rd Apr 2024
Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some
20 Years To $300k? Building A $10,000 Dividend Portfolio From Scratch
07:00am, Saturday, 20'th Apr 2024
Focusing on consistent dividend growth can lead to higher returns in lower-risk areas. The portfolio emphasizes companies with wide-moat business models, strong financials, and a commitment to shareho
Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline
11:06am, Friday, 19'th Apr 2024
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
06:51pm, Wednesday, 17'th Apr 2024
AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.
Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now
02:56pm, Tuesday, 16'th Apr 2024
Blue-chip dividend stocks have always been relevant. While they're not the most exciting investments, they provide a steady hand during market uncertainty.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:05am, Tuesday, 16'th Apr 2024
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is AbbVie a Millionaire Maker?
01:23am, Sunday, 14'th Apr 2024
AbbVie has a handful of desirable features as an investment. It's also navigating a period of uncertainty successfully so far.
AbbVie: Bulletproof Fundamentals
02:10pm, Friday, 12'th Apr 2024
AbbVie is a profitability superstar with a strong track record of success, generating almost 40% in free cash flow margin. The company has a diverse portfolio of products across several promising drug
